干预治疗药物，了解 2 型糖尿病缓解途径：第 2 部分。
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.
机构信息
Division of Pediatric Endocrinology, Children's Healthcare of Atlanta, Emory University School of Medicine, 1400 Tullie Road Northeast, Atlanta, GA 30329, USA.
Division of Endocrinology, Metabolism & Lipids, Emory University School of Medicine, 69 Jesse Hill Jr Drive Southeast, Glenn Building, Atlanta, GA 30303, USA.
出版信息
Endocrinol Metab Clin North Am. 2023 Mar;52(1):39-47. doi: 10.1016/j.ecl.2022.07.004. Epub 2022 Nov 18.
Abstract
Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Newer agents, such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual incretin agonists, can augment β-cell function and delay the need for additional antihyperglycemics. However, the effect on β-cell function ceases after stopping the medications. When combined with intensive lifestyle modifications, higher doses of GLP-1RA than those used for diabetes treatment can be used to induce weight loss. More research is needed on whether the weight loss achieved with GLP1-RA can be sustained after stopping medication and in turn can sustain diabetes remission.
摘要
2 型糖尿病的特征是胰腺β细胞功能进行性下降。新型药物，如胰高血糖素样肽-1 受体激动剂（GLP-1RA）和双重肠促胰岛素激动剂，可以增强β细胞功能，并延缓对其他抗高血糖药物的需求。然而，停止药物治疗后，这种作用就会停止。当与强化生活方式改变相结合时，GLP-1RA 的剂量可以高于治疗糖尿病的剂量，以诱导体重减轻。需要更多的研究来确定 GLP1-RA 治疗后体重减轻是否可以持续，以及是否可以维持糖尿病缓解。
相似文献
1
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.干预治疗药物，了解 2 型糖尿病缓解途径：第 2 部分。
Endocrinol Metab Clin North Am. 2023 Mar;52(1):39-47. doi: 10.1016/j.ecl.2022.07.004. Epub 2022 Nov 18.
2
GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.2型糖尿病中的胰高血糖素样肽-1受体激动剂
Curr Diabetes Rev. 2020;16(4):279-292. doi: 10.2174/1573399815666190502114924.
3
Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.术前使用胰高血糖素样肽-1 受体激动剂治疗减轻体重可预测 2 型糖尿病患者接受医学体重管理与减重手术联合治疗时可实现更大程度的体重减轻：一项纵向分析。
Diabetes Obes Metab. 2018 Mar;20(3):745-748. doi: 10.1111/dom.13131. Epub 2017 Nov 22.
4
Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.胰高血糖素样肽-1 受体激动剂与二肽基肽酶-4 抑制剂治疗 2 型糖尿病的疗效比较：一项随机临床试验的荟萃分析。
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:68-76. doi: 10.1111/dom.13137.
5
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.GLP-1 受体激动剂在 2 型糖尿病治疗中的作用和临床经验。
Postgrad Med. 2020 Nov;132(sup2):3-14. doi: 10.1080/00325481.2020.1798099. Epub 2020 Sep 8.
6
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?GLP-1 激动剂治疗肥胖和预防心血管疾病：我们目前取得了哪些进展？
Curr Atheroscler Rep. 2022 Nov;24(11):867-884. doi: 10.1007/s11883-022-01062-2. Epub 2022 Aug 31.
7
Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?是否到了为没有糖尿病的患者扩大使用胰高血糖素样肽-1 受体激动剂来减肥的时候了？
Drugs. 2021 Jun;81(8):881-893. doi: 10.1007/s40265-021-01525-x. Epub 2021 Apr 30.
8
9
Newer GLP-1 receptor agonists and obesity-diabetes.新型 GLP-1 受体激动剂与肥胖-糖尿病。
Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009.
10
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
引用本文的文献
1
Construction and Implications of Nomogram for Predicting Sustained Glycemic Remission After Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes.新诊断2型糖尿病短期强化胰岛素治疗后持续血糖缓解预测列线图的构建及意义
J Diabetes. 2025 Aug;17(8):e70135. doi: 10.1111/1753-0407.70135.
2
Multidisciplinary lifestyle treatment for type 2 diabetes in 12 European countries: protocol for a quasi-experimental study.12个欧洲国家2型糖尿病的多学科生活方式治疗：一项准实验研究方案
BMC Public Health. 2025 Mar 19;25(1):1069. doi: 10.1186/s12889-025-22246-w.
3
Use of Monoterpenes as Potential Therapeutics in Diabetes Mellitus: A Prospective Review.单萜类化合物作为糖尿病潜在治疗药物的应用：一项前瞻性综述。
Adv Pharmacol Pharm Sci. 2023 Nov 15;2023:1512974. doi: 10.1155/2023/1512974. eCollection 2023.
本文引用的文献
1
Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D).2 型糖尿病药物与代谢手术随机试验联盟中的糖尿病缓解（ARMMS-T2D）。
Diabetes Care. 2022 Jul 7;45(7):1574-1583. doi: 10.2337/dc21-2441.
2
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.度拉糖肽皮下注射与安慰剂联合滴定的胰岛素甘精胰岛素对 2 型糖尿病患者血糖控制的影响：SURPASS-5 随机临床试验。
JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078.
3
A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities.青少年2型糖尿病干预试验综述：挑战与机遇
Diabetes Ther. 2021 Nov;12(11):2827-2856. doi: 10.1007/s13300-021-01136-5. Epub 2021 Sep 23.
4
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.共识报告：2型糖尿病缓解的定义与解读
Diabetes Care. 2021 Aug 30;44(10):2438-44. doi: 10.2337/dci21-0034.
5
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.每周一次替西帕肽与每日一次德谷胰岛素联用，或不联用 SGLT2 抑制剂，作为二甲双胍的附加疗法治疗 2 型糖尿病患者（SURPASS-3）：一项随机、开放标签、平行分组、3 期临床试验。
Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6.
6
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.新型双重 GIP 和 GLP-1 受体激动剂替西帕肽在 2 型糖尿病患者中的疗效和安全性（SURPASS-1）：一项双盲、随机、3 期临床试验。
Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27.
7
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.替尔泊肽与司美格鲁肽每周一次治疗 2 型糖尿病患者的疗效比较。
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
8
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响：STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
9
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.司美格鲁肽 2·4 毫克每周一次治疗超重或肥胖、以及 2 型糖尿病成人患者（STEP 2）：一项随机、双盲、双模拟、安慰剂对照、3 期临床试验。
Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2.
10
Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.利拉鲁肽治疗对2型糖尿病儿童和青少年体重指数及体重参数的影响：ELLIPSE试验的事后分析
Pediatr Obes. 2021 Aug;16(8):e12778. doi: 10.1111/ijpo.12778. Epub 2021 Feb 25.
Zotero 插件